Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Grisnilimab setaritox

(Synonyms: WT1-RTA) Copy Product Info
🥰Excellent

Synonyms: WT1-RTA

Catalog No. T82259 Copy Product Info
🥰Excellent
Grisnilimab setaritox (WT1-RTA), an anti-CD7 antihuman T cell antibody linked to ricin A chain (RTA), exhibits in vitro cytotoxicity against CEM (T-lymphoblastic leukemia) cells with an ID 50 of 53 pM. The 30-kDa RTA component disrupts the function of 60S ribosomal subunits. Additionally, Grisnilimab setaritox has demonstrated efficacy in ameliorating leukemic meningitis in a rhesus monkey model [1].

Grisnilimab setaritox

Cas No. 2361013-29-6
Pack SizePriceUSA StockGlobal StockQuantity
1 mgInquiry4-6 weeks4-6 weeks
5 mgInquiry4-6 weeks4-6 weeks
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Grisnilimab setaritox (WT1-RTA), an anti-CD7 antihuman T cell antibody linked to ricin A chain (RTA), exhibits in vitro cytotoxicity against CEM (T-lymphoblastic leukemia) cells with an ID 50 of 53 pM. The 30-kDa RTA component disrupts the function of 60S ribosomal subunits. Additionally, Grisnilimab setaritox has demonstrated efficacy in ameliorating leukemic meningitis in a rhesus monkey model [1].
In vitro
Grisnilimab setaritox (2.5 μg/mL; 24 h) exhibits cytotoxicity against T-lymphoblastic leukemia CEM cells [1].
In vivo
Grisnilimab setaritox (60 μg, 120 μg; intrathecal or intravenous injection; single dose) demonstrated potential in inhibiting T-ALL meningeal leukemia in a rhesus macaque model [1]. Additionally, grisnilimab setaritox (60 μg; intravenous injection; once weekly for six weeks, or daily for seven days) induced CSF granulocytosis and anti-immunotoxin antibodies in the same model [1].
SynonymsWT1-RTA
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
TargetCD7
Chemical Properties
Cas No.2361013-29-6
Storage & Solubility Information
Storage-20°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: Grisnilimab setaritox in vivo | Grisnilimab setaritox in vitro